Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Nomura Initiates Coverage on HENGRUI PHARMA with Rating Neutral, TP HKD71.5
Recommend 7 Positive 11 Negative 5 |
||||
|
||||
|
Nomura has published a report initiating coverage on HENGRUI PHARMA (01276.HK)'s H-shares with a target price of HKD71.5 and a Neutral rating. The broker predicted HENGRUI PHARMA's revenue to grow by 13.3% and 11.5% YoY to RMB31.7 billion and RMB35.3 billion in FY25 and FY26, respectively. Its earnings for FY25 and FY26 are projected to increase by 25% and 19% YoY to RMB7.9 billion and RMB9.4 billion. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
